EUVIMEDEUVIMED entdecken
Crossref

Reprogramming Postablation Tumor Immune Microenvironment with Dual-Function Nanotherapeutic Immunomodulator for Synergistic Antitumor Immunity and Recurrence Suppression

Bing Wang, Zhicheng Yan, Yuhan Shen, Shumin Fan, Song Wang, Wenbo Wang, Qiang Zhang iD, Wei Yang, Bing He, Hao Wu iD

ACS Nano · 2026

DOI: 10.1021/acsnano.5c10858 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Nano, 2026. Verfasst von Bing Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Ultrasound, Peking University Cancer Hospi…. Hauptthemen laut MEDLINE: Tumor Microenvironment, Immunologic Factors, Nanoparticles, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Beijing Municipal Health Commission, Natural Science Foundation of Beijing Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Radiofrequency ablation (RFA) has emerged as a predominant minimally invasive approach for liver tumors, achieving favorable therapeutic outcomes and triggering a systemic immune response via the release of tumor-associated antigens. However, postablation tumor recurrence remains a critical challenge in clinics. Our previous studies revealed that ablation-induced immunosuppression, primarily characterized by the expansion and activation of myeloid-derived suppressor cells (MDSCs), critically compromised the host's antitumor immunity, impeding residual tumor eradication and fostering a permissive niche for recurrence. To decisively address this fundamental limitation and harness the potential of ablation to stimulate antitumor immunity, we proposed a nanotherapeutic immunomodulatory strategy that synchronously reversed postablation MDSC-driven immunosuppression ("release the immunosuppressive brakes") while activating the stimulator of interferon gene (STING) pathway-mediated antitumor immune priming ("apply the immunostimulatory accelerator") in the systemic immune landscape. Through rational design, we engineered the nanotherapeutic immunomodulators (termed cA@NPs, where NPs are nanoparticles) coencapsulating the STING agonist 2',3'-cyclic guanosine adenosine monophosphate (cGAMP) and the MDSC-differentiating agent all-trans retinoic acid (ATRA), effectively overcoming their disparate pharmacokinetic profiles while ensuring spatiotemporally coordinated delivery. The residual tumor models provided definitive evidence that reversing postablation MDSC-driven immunosuppression was essential for achieving more effective antitumor immunity. Comprehensive preclinical evaluations further demonstrated the cA@NPs' robust capacity to suppress micrometastasis, distant tumors, and orthotopic lesions via multidimensional remodeling of the postablation immune landscape. These findings established a mechanistic foundation for the clinical translation of ablation-synergized nanotherapy, effectively bridging localized thermal intervention with systemic immune potentiation to address tumor recurrence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tumor MicroenvironmentImmunologic FactorsNanoparticlesNeoplasm Recurrence, LocalAntineoplastic AgentsAnimalsMiceMyeloid-Derived Suppressor CellsRadiofrequency AblationNucleotides, CyclicHumansCell Line, TumorSTING ProteinMice, Inbred C57BL

Stichwörter der Autor:innen

STING pathway activationimmunosuppressionmyeloid-derived suppressor cellsradiofrequency ablationtumor recurrence

Substanzen

Immunologic FactorsNucleotides, CyclicAntineoplastic Agentscyclic guanosine monophosphate-adenosine monophosphateSTING Protein

Autor:innen und Institutionen

  • Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Ultrasound, Peking University Cancer Hospital & Institute, Peking University, Beijing 100142, China.
  • Beijing Key Laboratory of Molecular Pharmaceutics and Drug Delivery Systems, School of Pharmaceutical Sciences, Peking University, Beijing 100191,China.
  • State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.
  • Peking University Hospital of Stomatology, Beijing 100081, China.

ORCID-Profile: Qiang Zhang, Hao Wu

Förderung

  • National Key Research and Development Program of China
  • Beijing Municipal Health Commission
  • Natural Science Foundation of Beijing Municipality
  • National Natural Science Foundation of China
  • Natural Science Foundation of Shandong Province
  • Peking University Cancer Hospital

Zitieren

APA

Wang, B., Yan, Z., Shen, Y., Fan, S., Wang, S., Wang, W., Zhang, Q., Yang, W., He, B., & Wu, H. (2026). Reprogramming Postablation Tumor Immune Microenvironment with Dual-Function Nanotherapeutic Immunomodulator for Synergistic Antitumor Immunity and Recurrence Suppression. ACS Nano. https://doi.org/10.1021/acsnano.5c10858

Vancouver

Wang B, Yan Z, Shen Y, Fan S, Wang S, Wang W, et al. Reprogramming Postablation Tumor Immune Microenvironment with Dual-Function Nanotherapeutic Immunomodulator for Synergistic Antitumor Immunity and Recurrence Suppression. ACS Nano. 2026. doi:10.1021/acsnano.5c10858

BibTeX
@article{Wang2026,
  author = {Wang, Bing and Yan, Zhicheng and Shen, Yuhan and Fan, Shumin and Wang, Song and Wang, Wenbo and Zhang, Qiang and Yang, Wei and He, Bing and Wu, Hao},
  title = {Reprogramming Postablation Tumor Immune Microenvironment with Dual-Function Nanotherapeutic Immunomodulator for Synergistic Antitumor Immunity and Recurrence Suppression},
  journal = {ACS Nano},
  year = {2026},
  doi = {10.1021/acsnano.5c10858}
}
Kostenlos starten →